100 related articles for article (PubMed ID: 36206301)
21. Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Ho GY; Kyran EL; Bedo J; Wakefield MJ; Ennis DP; Mirza HB; Vandenberg CJ; Lieschke E; Farrell A; Hadla A; Lim R; Dall G; Vince JE; Chua NK; Kondrashova O; Upstill-Goddard R; Bailey UM; Dowson S; Roxburgh P; Glasspool RM; Bryson G; Biankin AV; ; Cooke SL; Ratnayake G; McNally O; Traficante N; ; DeFazio A; Weroha SJ; Bowtell DD; McNeish IA; Papenfuss AT; Scott CL; Barker HE
Cancer Res; 2022 Dec; 82(23):4457-4473. PubMed ID: 36206301
[TBL] [Abstract][Full Text] [Related]
22. Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
[TBL] [Abstract][Full Text] [Related]
23. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.
Dezső Z; Oestreicher J; Weaver A; Santiago S; Agoulnik S; Chow J; Oda Y; Funahashi Y
PLoS One; 2014; 9(8):e106131. PubMed ID: 25171249
[TBL] [Abstract][Full Text] [Related]
25. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
26. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis.
Amant F; Vloeberghs V; Woestenborghs H; Moerman P; Vergote I
Gynecol Oncol; 2003 Aug; 90(2):372-7. PubMed ID: 12893202
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic Insights Delineating the Role of Cholesterol in Epithelial Mesenchymal Transition and Drug Resistance in Cancer.
Abdulla N; Vincent CT; Kaur M
Front Cell Dev Biol; 2021; 9():728325. PubMed ID: 34869315
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis.
Tanni KA; Truong CB; Johnson BS; Qian J
Crit Rev Oncol Hematol; 2021 Jul; 163():103375. PubMed ID: 34087344
[TBL] [Abstract][Full Text] [Related]
29. High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.
Gatti G; Betts C; Rocha D; Nicola M; Grupe V; Ditada C; Nuñez NG; Roselli E; Araya P; Dutto J; Boffelli L; Fernández E; Coussens LM; Maccioni M
Breast Cancer Res; 2021 Mar; 23(1):40. PubMed ID: 33766090
[TBL] [Abstract][Full Text] [Related]
30.
Raieli S; Di Renzo D; Lampis S; Amadesi C; Montemurro L; Pession A; Hrelia P; Fischer M; Tonelli R
Front Oncol; 2021; 11():625207. PubMed ID: 33718189
[TBL] [Abstract][Full Text] [Related]
31. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities.
Huang B; Song BL; Xu C
Nat Metab; 2020 Feb; 2(2):132-141. PubMed ID: 32694690
[TBL] [Abstract][Full Text] [Related]
32. Destruction of a Microtubule-Bound MYC Reservoir during Mitosis Contributes to Vincristine's Anticancer Activity.
Becker S; Kiecke C; Schäfer E; Sinzig U; Deuper L; Trigo-Mourino P; Griesinger C; Koch R; Rydzynska Z; Chapuy B; von Bonin F; Kube D; Venkataramani V; Bohnenberger H; Leha A; Flach J; Dierks S; Bastians H; Maruschak B; Bojarczuk K; Taveira MO; Trümper L; Wulf GM; Wulf GG
Mol Cancer Res; 2020 Jun; 18(6):859-872. PubMed ID: 32161139
[TBL] [Abstract][Full Text] [Related]
33. Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma.
Gotoh O; Sugiyama Y; Takazawa Y; Kato K; Tanaka N; Omatsu K; Takeshima N; Nomura H; Hasegawa K; Fujiwara K; Taki M; Matsumura N; Noda T; Mori S
Nat Commun; 2019 Oct; 10(1):4965. PubMed ID: 31672974
[TBL] [Abstract][Full Text] [Related]
34. Genomics of gynaecological carcinosarcomas and future treatment options.
Barker HE; Scott CL
Semin Cancer Biol; 2020 Apr; 61():110-120. PubMed ID: 31622660
[TBL] [Abstract][Full Text] [Related]
35. Topconfects: a package for confident effect sizes in differential expression analysis provides a more biologically useful ranked gene list.
Harrison PF; Pattison AD; Powell DR; Beilharz TH
Genome Biol; 2019 Mar; 20(1):67. PubMed ID: 30922379
[TBL] [Abstract][Full Text] [Related]
36. Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 May; 38(5):2929-2938. PubMed ID: 29715119
[TBL] [Abstract][Full Text] [Related]
37. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
[TBL] [Abstract][Full Text] [Related]
38. Toll-like receptors 7 and 8 expression correlates with the expression of immune biomarkers and positively predicts the clinical outcome of patients with melanoma.
Zhang M; Yan Z; Wang J; Yao X
Onco Targets Ther; 2017; 10():4339-4346. PubMed ID: 28919783
[TBL] [Abstract][Full Text] [Related]
39. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
Katakami N; Felip E; Spigel DR; Kim JH; Olivo M; Guo M; Nokihara H; Yang JC; Iannotti N; Satouchi M; Barlesi F
Ann Oncol; 2017 Sep; 28(9):2241-2247. PubMed ID: 28911085
[TBL] [Abstract][Full Text] [Related]
40. The LIN28/let-7 Pathway in Cancer.
Balzeau J; Menezes MR; Cao S; Hagan JP
Front Genet; 2017; 8():31. PubMed ID: 28400788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
